Sofosbuvir targets the NS5B RNA polymerase, while daclatasvir inhibits the NS5A protein essential for viral assembly and replication. Their combination enhances antiviral efficacy and minimises resistance.
Recommended for:
Adult patients with chronic hepatitis C (especially genotypes 1 and 3)
Treatment-naïve and relapsed patients
Patients with compensated cirrhosis
Interferon-free therapy protocols
Only under specialist supervision
Chronic hepatitis C infection
Used in adults as part of interferon-free combination therapy
The tablets are taken orally once daily, with or without food. The treatment duration ranges from 12 to 24 weeks depending on the HCV genotype, cirrhosis status, and patient response.
Contraindications:
Hypersensitivity to sofosbuvir or daclatasvir
Concomitant use with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine)
Pregnancy and breastfeeding
Paediatric patients (under 18 years)
Side Effects:
Headache
Fatigue
Insomnia
Nausea
Diarrhoea
Elevated liver enzymes
Hypersensitivity reactions